India, March 10 -- Shares of Trevi Therapeutics, Inc. (TRVI) surged over 40% on Monday morning after the company announced positive topline results from the phase 2a trial of Haduvio in patients with refractory chronic cough.
TRVI is currently trading at $6.09, up $1.78 or 41.46%, on heavy volume of 38 million shares, above average volume of nearly 2 million, on the Nasdaq. The stock opened its trading at $6.59 after closing Friday. The stock has traded between $2.30 and $7.39 in the past 52-week period.
Haduvio met the primary endpoint with a statistically-significant reduction in 24-hour cough frequency with a 57% placebo-adjusted change from baseline. Haduvio showed similar efficacy in patients with moderate or severe cough counts.
go...